PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Negative revenue growth while CRVO stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-116.81%
Negative gross profit growth while CRVO is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-52.01%
Negative EBIT growth while CRVO is at 6.20%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-52.01%
Negative operating income growth while CRVO is at 6.78%. Joel Greenblatt would press for urgent turnaround measures.
-52.47%
Negative net income growth while CRVO stands at 7.43%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.48%
Negative EPS growth while CRVO is at 7.51%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.48%
Negative diluted EPS growth while CRVO is at 7.51%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.17%
Share count expansion well above CRVO's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.17%
Diluted share count expanding well above CRVO's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
582.93%
OCF growth above 1.5x CRVO's 15.28%. David Dodd would confirm a clear edge in underlying cash generation.
577.68%
FCF growth above 1.5x CRVO's 15.28%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
10Y OCF/share CAGR above 1.5x CRVO's 99.94%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
131.96%
5Y OCF/share CAGR 1.25-1.5x CRVO's 98.97%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
210.81%
3Y OCF/share CAGR above 1.5x CRVO's 94.07%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
88.12%
Net income/share CAGR at 75-90% of CRVO's 100.00%. Bill Ackman would press for strategic moves to boost long-term earnings.
91.00%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
67.11%
3Y net income/share CAGR 50-75% of CRVO's 93.51%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
1963.85%
10Y equity/share CAGR above 1.5x CRVO's 100.03%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-27.97%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
5.99%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.97%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
1244.16%
Debt growth of 1244.16% while CRVO is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
6.71%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
86.34%
SG&A growth well above CRVO's 0.41%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.